利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.025 秒)

    Method of activating insulin receptor substrate-2 to stimulate insulin production
    1.
    发明申请
    Method of activating insulin receptor substrate-2 to stimulate insulin production 审中-公开
    激活胰岛素受体底物-2以刺激胰岛素生成的方法

    公开(公告)号：US20050250676A1

    公开(公告)日：2005-11-10

    申请号：US11179972

    申请日：2005-07-11

    申请人： Gerhard Seipke ,  Irini Rakatzi ,  Olaf Dransfeld ,  Jurgen Eckel

    发明人： Gerhard Seipke ,  Irini Rakatzi ,  Olaf Dransfeld ,  Jurgen Eckel

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28

    摘要： The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.

    摘要翻译： 本发明涉及用于治疗糖尿病患者，糖尿病前期患者和患有糖尿病风险或葡萄糖耐量降低的患者的新方法和组合物。 在一个实施方案中，本发明涉及激活胰岛素受体底物-2以防止β细胞团的损失，保护β细胞功能丧失，恢复β细胞的质量，恢复β细胞功能或其任何组合，从而利用 有效量的Lys B3，Glu B29胰岛素给需要这种治疗的患者。

    METHOD OF ACTIVATING INSULIN RECEPTOR SUBSTRATE-2 TO STIMULATE INSULIN PRODUCTION
    2.
    发明申请
    METHOD OF ACTIVATING INSULIN RECEPTOR SUBSTRATE-2 TO STIMULATE INSULIN PRODUCTION 审中-公开
    激活胰岛素受体底物-2刺激胰岛素生产的方法

    公开(公告)号：US20070099821A1

    公开(公告)日：2007-05-03

    申请号：US11609530

    申请日：2006-12-12

    申请人： Gerhard Seipke ,  Irini Rakatzi ,  Olaf Dransfeld ,  Jurgen Eekel

    发明人： Gerhard Seipke ,  Irini Rakatzi ,  Olaf Dransfeld ,  Jurgen Eekel

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28

    摘要： The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.

    摘要翻译： 本发明涉及用于治疗糖尿病患者，糖尿病前期患者和患有糖尿病风险或葡萄糖耐量降低的患者的新方法和组合物。 在一个实施方案中，本发明涉及激活胰岛素受体底物-2以防止β细胞团的损失，保护β细胞功能丧失，恢复β细胞的质量，恢复β细胞功能或其任何组合，从而利用 有效量的Lys B3，Glu B29胰岛素给需要这种治疗的患者。

    Method of activating insulin receptor substrate-2 to stimulate insulin production
    3.
    发明申请
    Method of activating insulin receptor substrate-2 to stimulate insulin production 审中-公开
    激活胰岛素受体底物-2以刺激胰岛素生成的方法

    公开(公告)号：US20060172923A1

    公开(公告)日：2006-08-03

    申请号：US11398869

    申请日：2006-04-06

    申请人： Gerhard Seipke ,  Irini Rakatzi ,  Olaf Dransfeld ,  Juergen Eckel

    发明人： Gerhard Seipke ,  Irini Rakatzi ,  Olaf Dransfeld ,  Juergen Eckel

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28

    摘要： The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LySB3,GluB29 insulin to patients in need of this treatment.

    摘要翻译： 本发明涉及用于治疗糖尿病患者，糖尿病前期患者和患有糖尿病风险或葡萄糖耐量降低的患者的新方法和组合物。 在一个实施方案中，本发明涉及激活胰岛素受体底物-2以防止β细胞团的损失，保护β细胞功能丧失，恢复β细胞的质量，恢复β细胞功能或其任何组合，从而利用 有效量的LysS B3，Glu B29胰岛素给需要这种治疗的患者。

    Insulin analogs with enhanced zinc binding
    4.
    发明授权
    Insulin analogs with enhanced zinc binding 有权
    胰岛素类似物具有增强的锌结合

    公开(公告)号：US06686177B1

    公开(公告)日：2004-02-03

    申请号：US09701968

    申请日：2001-05-14

    申请人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke ,  Axel Wollmer

    发明人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke ,  Axel Wollmer

    IPC分类号： A61K3828

    CPC分类号： C07K14/62 ,  A61K38/00 ,  Y10S514/866

    摘要： The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.

    摘要翻译： 本发明涉及具有增强的锌结合能力的胰岛素类似物和与人胰岛素相比具有延迟活性的稳定的锌络合物。 本发明还涉及生产所述胰岛素类似物的方法及其用途，特别是用于治疗I型和II型糖尿病的药物制剂。

    Insulin derivatives having a rapid onset of action
    7.
    发明授权
    Insulin derivatives having a rapid onset of action 失效
    具有快速起效的胰岛素衍生物

    公开(公告)号：US06221633B1

    公开(公告)日：2001-04-24

    申请号：US09099307

    申请日：1998-06-18

    申请人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke

    发明人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke

    IPC分类号： C12N1517

    CPC分类号： C07K14/62 ,  A61K38/00 ,  C07K2319/00 ,  Y10S514/866

    摘要： The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.

    摘要翻译： 本发明涉及与人胰岛素相比，加速起效的胰岛素衍生物，其制备方法及其用途，特别是用于治疗糖尿病的药物制剂中。 特别地，本发明涉及胰岛素衍生物或其生理上可耐受的盐，其中B链B3位的天冬酰胺（Asn）被天然存在的碱性氨基酸残基和B27位置的至少一个氨基酸残基所取代， B链的B28或B29被另一个天然存在的氨基酸残基替代，其任选可能是由A，A，D，Gly，Ser，Thr或Ala代替的A链的第21位的天冬酰胺（Asn）和苯丙氨酸 Phe）在B链的位置B1和B链的位置B30的氨基酸残基不存在。

    Mini-proinsulin, its preparation and use
    8.
    发明授权
    Mini-proinsulin, its preparation and use 失效
    迷你胰岛素原，其制备和用途

    公开(公告)号：US06875589B1

    公开(公告)日：2005-04-05

    申请号：US08402394

    申请日：1995-03-10

    申请人： Michael Dörschug ,  Paul Habermann ,  Gerhard Seipke ,  Eugen Uhlmann

    发明人： Michael Dörschug ,  Paul Habermann ,  Gerhard Seipke ,  Eugen Uhlmann

    IPC分类号： A61K38/00 ,  C07K14/62 ,  C12N1/21 ,  C12N15/17 ,  A61K38/28 ,  C12N1/16

    CPC分类号： C07K14/62 ,  A61K38/00

    摘要： A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.

    摘要翻译： 其中氨基酸Arg桥接A和B链而不是C链的微型胰岛素原显示胰岛素活性，并且适用于制备用于治疗糖尿病的药物。 胰蛋白酶可以简单地转化为胰岛素衍生物，其中B链被Arg延长。 这可以使用羧肽酶B转化成胰岛素。然而，有益的是，微型胰岛素原也可以在一锅法中直接转化为胰岛素。